Neptune's Final Receipt for Resale Prospectus

Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX-V:NTB) announces the grant on September 23, 2011 of the final receipt by the securities regulatory authority in the Province of Québec in connection with the resale prospectus of Neptune.

This short form base shelf prospectus (the "Prospectus") allows the periodic resale from time to time by the Selling Securityholders identified under the heading "Selling Securityholders" on page 6 of the Prospectus available on SEDAR at www.sedar.com of some or all of 2,722,222 of our common shares and 680,556 warrants (the "US warrants"), currently held by the Selling Securityholders (the "offering"). Each whole warrant entitles the holder thereof to purchase one of Neptune common shares at a price of US$ 2.75 per share at any time on or before 4:00 p.m. (EDT) on October 27, 2012. In this Prospectus, we refer to the foregoing collectively as the "Registrable Securities."

This Prospectus was filed with the securities regulatory authority in the Province of Québec (the "Qualifying Jurisdiction"), in order to qualify the resale of the Registrable Securities in the United States.

The registration of the securities covered by this Prospectus does not necessarily mean that any of the securities will be offered or sold by the Selling Securityholders.

This Prospectus is part of a "shelf" registration statement filed with the Securities and Exchange Commission (the "SEC"). This Prospectus may be used by the Selling Securityholders in connection with resale of the Registrable Securities in the United States from time to time during the period that this Prospectus, including any amendments thereto, remains valid.

The Registrable Securities may be offered by the Selling Securityholders in negotiated transactions or otherwise, to or through underwriters or dealers purchasing as principal or directly to purchasers at varying prices determined at the time of the sale or at negotiated prices. In addition, the Registrable Securities may be offered from time to time through ordinary brokerage transactions on the TSXV or NASDAQ.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Corporation focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Corporation sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         +1.450.687.2262
         [e-mail]
         www.neptunebiotech.com
         
         CEOcast Contact:
         Dan Schustack
         [phone]
         [e-mail]
         www.ceocast.com
         
         Howard Group Contact:
         Dave Burwell
         [phone]
         [e-mail]
         www.howardgroupinc.com